Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
April 21 2022 - 6:00AM
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage
biotechnology company developing a new modality of orally delivered
medicines, today announced that John Maraganore, Ph.D., founder and
longtime former CEO of Alnylam Pharmaceuticals, and Tassos
Gianakakos, the longtime former CEO of MyoKardia, have joined Evelo
as strategic advisors.
“We are thrilled to welcome both John and Tassos as strategic
advisors to Evelo,” said Simba Gill, Ph.D., Chief Executive Officer
of Evelo. “John and Tassos’ long and remarkable track records in
building pioneering platform companies and innovative treatments
will hold us in good stead as we continue to execute on our
vision.”
About John MaraganoreDr. John Maraganore served
as the founding CEO and a Director of Alnylam from 2002 to 2021,
where he built and led the company from early platform research on
RNA interference through global approval and commercialization of
the first four RNAi therapeutic medicines. Before his time with
Alnylam, John’s long career in biotech included serving in
leadership roles across research, development and other areas at
Millennium Pharmaceuticals and Biogen. Dr. Maraganore received his
M.S. and Ph.D. in biochemistry and molecular biology at the
University of Chicago.
About Tassos GianakakosTassos Gianakakos served
for eight years as Chief Executive Officer of MyoKardia, a
company focused on developing innovative therapeutics to treat
genetic heart disease, until MyoKardia’s 2020 acquisition by
Bristol Myers Squibb. During his time, MyoKardia developed several
targeted cardiovascular medicines, including mavacamten for the
treatment of obstructive hypertrophic cardiomyopathy (“HCM”). Prior
to MyoKardia, his extensive experience included leadership roles at
MAP Pharmaceuticals (acquired by Allergan), Codexis Inc. and
Maxygen. Mr. Gianakakos holds B.Sc. degrees in chemical engineering
and economics from the Massachusetts Institute of Technology, an
M.Sc. in biotechnology from Northwestern University and an M.B.A.
from Harvard Business School.
About Evelo BiosciencesEvelo
Biosciences is a clinical stage biotechnology company
developing orally delivered product candidates that are designed to
act on the small intestinal axis, SINTAX™, with systemic
therapeutic effects. SINTAX plays a central role in governing the
immune, metabolic, and neurological systems. The Company’s first
product candidates are pharmaceutical preparations of single
strains of microbes selected for the potential to offer defined
pharmacological properties. Evelo’s therapies have the potential to
be effective, safe, and affordable medicines to improve the lives
of people with inflammatory diseases.
Evelo currently has two product candidates in development:
EDP1815 and EDP2939 for the treatment of inflammatory diseases.
Evelo is advancing additional product candidates in other disease
areas.
For more information, please visit www.evelobio.com and engage
with Evelo on LinkedIn.
Forward Looking StatementsThis press release
contains forward-looking statements including within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including statements concerning the development of our
product candidates.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: the impact of the COVID-19 pandemic on our operations,
including our preclinical studies and clinical trials, and the
continuity of our business; we have incurred significant losses,
are not currently profitable and may never become profitable; our
need for additional funding; our limited operating history; our
unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development,
including potential delays in regulatory approval; our reliance on
third parties and collaborators to expand our microbial library,
conduct our clinical trials, manufacture our product candidates,
and develop and commercialize our product candidates, if approved;
our lack of experience in manufacturing, selling, marketing, and
distributing our product candidates; failure to compete
successfully against other drug companies; protection of our
proprietary technology and the confidentiality of our trade
secrets; potential lawsuits for, or claims of, infringement of
third-party intellectual property or challenges to the ownership of
our intellectual property; our patents being found invalid or
unenforceable; risks associated with international operations; our
ability to retain key personnel and to manage our growth; the
potential volatility of our common stock; our management and
principal stockholders have the ability to control or significantly
influence our business; costs and resources of operating as a
public company; unfavorable or no analyst research or reports; and
securities class action litigation against us.
These and other important factors discussed under the caption
"Risk Factors" in our Annual Report on Form 10-K for the fiscal
year ended December 31, 2021, and our other reports filed with the
SEC, could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, except as required by law, we disclaim any obligation to do
so, even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
ContactsInvestors:Kendra
Sweeney, 239-877-7474ksweeney@evelobio.com
Media:Jessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Apr 2023 to Apr 2024